Spondyloarthritis & psoriatic arthritis
Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment Recommendations
Authors' conclusion
Several pharmacologic therapeutic classes have high-quality evidence demonstrating efficacy for cutaneous PsO in the PsA population.
Study context
- Population
- Patients with PsA in interventional RCTs (February 2013 to December 2021) reporting PASI75 for cutaneous psoriasis, blinded comparison period ≥ 10 weeks37 studies (40 treatment arms)
- Comparison
- Pharmacologic therapeutic classes vs placebo, and head-to-head
- Outcome
- Efficacy for cutaneous psoriasis (at least 75% improvement in the Psoriasis Area and Severity Index)
Methodological detailsGrading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology, literature review informing the 2021 GRAPPA treatment recommendations, 116 studies and 36 abstracts screened
- GRADE methodology
- Literature review informing the 2021 GRAPPA treatment recommendations
- 116 studies and 36 abstracts screened
Pooled result
As reported in the abstract
Efficacy for plaque psoriasis
- Phosphodiesterase 4 inhibitors, JAKi, tyrosine kinase 2 inhibitors, IL-17i, IL-12/23i, IL-23i and tumor necrosis factor inhibitors (TNFi): high-quality data broadly supporting efficacy of each class over placebo
- Head-to-head studies: high-quality data supported both IL-17i and IL-23i over TNFi
- GRADE quality: high
Original publication
Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol. Published 1 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →